王艳丽,朱晓青,孙佳,李勇军,刘春花,陆苑
WANG Yanli,ZHU Xiaoqing,SUN Jia,LI Yongjun,LIU Chunhua,LU Yuan

• 1:贵州医科大学贵州省药物制剂重点实验室&省部共建药用植物功效与利用国家重点实验室
• 2:贵州医科大学药学院
• 3:贵州医科大学民族药与中药开发应用教育部工程研究中心

摘要(Abstract)：

目的 研究艾迪注射液（ADI）对阿霉素（DOX）及其活性代谢产物阿霉素醇（DOXol）在H22肝癌模型小鼠体内组织分布的影响。方法 建立H22肝癌移植瘤小鼠模型，将模型小鼠随机分成DOX单次给药组（SDOX组）、DOX多次给药组（MDOX组）和ADI联合MDOX组（AMDOX组）。三组小鼠均造模15d，于造模结束2 h时收集各组小鼠的血液、肿瘤、心、肝、肾、肺组织，样本处理后，采用超高效液相串联质谱法（UPLC-MS/MS）测定DOX和DOXol浓度，比较各组小鼠DOX和DOXol的组织分布情况。结果 与SDOX组比较，MDOX组小鼠各组织中DOX和DOXol的含量均显著增加，差异有统计学意义（P<0.05）；联合用药后，DOX和DOXol除了在肿瘤部位的积累量明显增加外，在其余组织中均表现出不同程度的降低趋势，差异有统计学意义（P<0.05）。结论 ADI可能是通过增加肿瘤中DOX和DOXol浓度增强抗肿瘤能力，并且通过降低心脏中DOX和DOXol浓度、降低DOX的心脏毒性。
Objective To study the effect of Aidi injection(ADI) on biodistribution of doxorubicin(DOX) and its active metabolite doxorubicinol( DOXol) in mouse model of H22 hepatocellular carcinoma(HCC).Methods H22 HCC mouse model was established, and the model mice were randomly divided into single DOX(SDOX group), multiple DOX(MDOX group) and ADI combined MDOX(AMDOX group). It took 15 days to establish H22 HCC mouse model. Blood, tumor, heart,liver, kidney, and lung were collected at 2 hours after completing the modeling. The concentrations of DOX and DOXol were determined by ultra-high performance liquid chromatography-tandem mass spectrometry(UPLC-MS/MS). The biodistribution of DOX and DOXol were compared among three groups.Results Compared with SDOX group, the contents of DOX and DOXol in MDOX group were significantly increased(P< 0. 05). The contents of DOX and DOXol in the tumors were significantly increased, but displayed a decreased trend in the rest of tissues in AMDOX group(P< 0. 05).Conclusion ADI may enhance the antitumor ability by increasing the concentration of DOX and DOXol in the tumor and reduce the cardiotoxicity of DOX by decreasing the concentration of DOX and DOXol in the heart.

关键词(KeyWords)： 艾迪注射液;H22肝癌模型;阿霉素;阿霉素醇;组织分布
aidi injection(ADI);H22 tumor-bearing mice;doxorubicin(DOX);doxorubicinol(DOXol);biodistribution

Abstract:

Keywords:

基金项目(Foundation): 国家自然科学基金项目（81860718）;; 贵州省科技厅（黔科合支撑[2021]一般421）;; 2021年度贵州省卫生健康委科学技术基金项目（gzwkj2021-450）;; 贵州省教育厅青年科技人才成长项目（黔教合KY字[2021]171）

作者(Author): 王艳丽,朱晓青,孙佳,李勇军,刘春花,陆苑
WANG Yanli,ZHU Xiaoqing,SUN Jia,LI Yongjun,LIU Chunhua,LU Yuan

DOI: 10.19367/j.cnki.2096-8388.2022.03.001

参考文献(References)：

• [1] VILLANUEV A A. Hepatocellular carcinoma[J]. The New England Journal of Medicine, 2019, 380(15):1450-1462.
• [2] SUNG H, FERLAY J, SIEGEL R L, et al. Global cancer statistics 2020:globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3):209-249.
• [3] CHEN Z, XIE H, HU M, et al. Recent progress in treatment of hepatocellular carcinoma[J]. American Journal of Cancer Research, 2020, 10(9):2993-3036.
• [4] COX J, WEINMAN S. Mechanisms of doxorubicin resistance in hepatocellular carcinoma[J]. Hepatic oncology,2016, 3(1):57-59.
• [5] CAROLINE F T, CONNIE O, SHARON M, et al. Doxorubicin pathways:pharmacodynamics and adverse effects[J]. Pharmacogenetics and Genomics, 2011, 21(7):440-446.
• [6]中华人民共和国国家卫生健康委员会医政医管局．原发性肝癌诊疗规范（2019年版）[J]．肿瘤综合治疗电子杂志，2020, 6(2):55-85.
• [7] XIE G, CUI Z H, PENG K, et al. Aidi injection, a Traditional chinese medicine injection, could be used as an adjuvant drug to improve quality of life of cancer patients receiving chemotherapy:a propensity score matching analysis[J]. Integrative Cancer Therapies, 2019,18:1534735418810799.
• [8] XIAO Z, WANG C Q, LI L H, et al. Clinical efficacy and safety of aidi injection plus docetaxel-based chemotherapy in advanced nonsmall cell lung cancer:a meta-analysis of 36randomized controlled trials[J]. Evidence-Based Complementary and Alternative Medicine, 2018, 2018:7918258.
• [9]巩仔鹏，陈颖，张瑞杰，等．疾病状态下的中药药代动力学研究进展[J]．中国中药杂志，2015, 40(2):169-173.
• [10]LU Y, PAN J, ZHU X Q, et al. Pharmacokinetic herbdrug interactions between Aidi injection and doxorubicin in rats with diethylnitrosamine-induced hepatocellular carcinoma[J]. BMC Pharmacology and Toxicology, 2021,22(1):48-48.
• [11]夏猛，孙玉浩，王萌，等．原发性肝癌常见动物模型的研究进展[J]．临床肝胆病杂志，2021, 37(8):1938-1942.
• [12]李军，王庆学，王镜辉，等．肝癌研究中常用造模方法的应用概况及特点[J]．贵阳中医学院学报，2019,41(2):97-100.
• [13]陆苑，潘洁，杨淑婷，等．UPLC-MS法研究艾迪注射液对大鼠体内阿霉素药代动力学的影响[J]．中国药理学通报，2018, 34(3):423-427.
• [14] MARCO V, ROBERTO M, ANDREA R. Multimodal treatment of hepatocellular carcinoma on cirrhosis:an update[J]. World Journal of Gastroenterology, 2013, 19(42):7316-7326.
• [15]PATRICIA R. Systemic therapy of hepatocellular carcinoma:Are we making progress[J]. Advances in Therapy,2008, 25(11):1089-1104.
• [16]KIM D W, TALATI C, KIM R. Hepatocellular carcinoma(HCC):beyond sorafenib-chemotherapy[J]. Journal of gastrointestinal oncology, 2017, 8(2):256-265.
• [17]YU C F, JIANG Z H, HOU A H, et al. Shen-Cao granules formulated based on traditional Chinese medicine alleviates bone marrow suppression caused by platinumbased anticancer reagents[J]. Medicine, 2017, 96(19):e6818-e6818.
• [18]郝明志，陈武进，林海澜，等．肝动脉化疗栓塞术联合中药治疗原发性肝癌的临床疗效观察[J]．中国医药指南，2012, 10(34):4-7.
• [19]LIU X L, LI M, WANG X H, et al. Effects of adjuvant traditional Chinese medicine therapy on long-term survival in patients with hepatocellular carcinoma[J]. Phytomedicine, 2019, 62:152930.
• [20]程宏文，骆明莲，江涛，等．艾迪注射液联合FOLFOX4化疗治疗原发性肝癌疗效观[J]．现代肿瘤医学，2012, 20(4):777-779.
• [21]阿衣夏木古丽，柳江．艾迪注射液联合肝动脉灌注栓塞治疗原发性肝癌108例临床观[J]．现代肿瘤医学，2011, 19(1):111-114..
• [22]MALECKOVA A, TONAR Z, MIK P, et al. Animal models of liver diseases and their application in experimental surgery[J]. Rozhledy V Chirurgii:Mesicnik Ceskoslovenske Chirurgicke Spolecnosti, 2019, 98(3):100-109.
• [23]朱晓青，陆苑，刘亭，等．艾迪注射液对DEN诱导型肝癌大鼠体内细胞色素P450酶表达的影响[J]．中国实验方剂学杂志，2021, 27(8):43-49.
• [24]韦武，郭红星．大鼠肝癌模型建立的研究进展[J]．中国实验动物学报，2019, 27(1):119-123.
• [25]孙振宇，武鸿彪，刘宁，等．小鼠原发性肝癌模型的建立与优化[J]．中国比较医学杂志，2019, 29(11):22-27.
• [26]李晓娟，白云峰，崔智，等．常用实验动物肝癌模型研究进展[J]．中国比较医学杂志，2012, 22(4):73-77.
• [27]BALARAMAN K. Teaching the basics of the mechanism of doxorubicin-induced cardiotoxicity:have we been barking up the wrong tree[J]. Redox Biology, 2020, 29:101394.
• [28] RICHARD D O, PHILLIP S M, DEAN E B, et al.Doxorubicin cardiotoxicity may be caused by its metabolite, doxorubicinol[J]. Proceedings of the National Academy of Sciences of the United States of America,1988, 85(10):3585-3589.
• [29]CRISTINA C, RENATO X S, SUSANA C, et al. Doxorubicin:the good, the bad and the ugly effect[J]. Current Medicinal Chemistry, 2009, 16(25):3267-3285.
• [30]NIITSU N, KASUKABE T, YOKOYAMA A, et al. Anticancer derivative of butyric acid(Pivalyloxymethyl butyrate)specifically potentiates the cytotoxicity of doxorubicin and daunorubicin through the suppression of microsomal glycosidic activity[J]. Molecular Pharmacology,2000, 58(1):27-36.
• [31]FILOMENI G, TURELLA P, DUPUIS M L, et al. 6-（7-Nitro-2,1,3-benzoxadiazol-4-ylthio） hexanol, a specific glutathione S-transferase inhibitor, overcomes the multidrug resistance(MDR)-associated protein 1-mediated MDR in small cell lung cancer[J]. Molecular Cancer Therapeutics, 2008, 7(2):371-379.
• [32] BAINS O, KARKLING M J, GRIGLIATTI T A, et al.Two nonsynonymous single nucleotide polymorphisms of human carbonyl reductase 1 demonstrate reduced in vitro metabolism of daunorubicin and doxorubicin[J]. Drug Metabolism and Disposition:the Biological Fate of Chemicals, 2009, 37(5):1107-1114.
• [33]陆苑，潘洁，杨淑婷，等．艾迪注射液对肝癌大鼠谷胱甘肽-S-转移酶的影响[J]．中国药理学通报，2018,34(8):1170-1174.
• [34]ABOLFAZL F, HAMID R D M, MARYAM M, et al.Association of ABCB1 and SLC22A16 gene polymorphisms with incidence of doxorubicin-induced febrile neutropenia:a survey of iranian breast cancer patients[J].PLOS ONE, 2016, 11(12):e0168519.
• [35]GOLAM K, HIROTO H, KOSUKE A, et al. Comparative study of the sensitivities of cancer cells to doxorubicin, and relationships between the effect of the drug-efflux pump p-gp[J]. Biological and Pharmaceutical Bulletin, 2014, 37(12):1926-1935.
• [36]MA J J,LIU H P. Efficacy of aidi injection on overexpression of p-glycoprotein induced by vinorelbine and cisplatin regimen in patients with non-small cell lung cancer[J]. Chinese Journal of Integrative Medicine, 2017, 23(7):504-509.

文章评论(Comment)：